BIOMEDICAL TECHNOLOGY SOLUTIONS HOLDINGS INC
CIK:0001443062|SEC Filings
|
Consolidated Statements of Operations (Unaudited) (USD $)
|
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2011
|
Sep. 30, 2010
|
Sep. 30, 2011
|
Sep. 30, 2010
|
|
| Net sales | $ 200,711 | $ 238,298 | $ 543,033 | $ 539,988 |
| Operating Costs and Expenses: | ||||
| Cost of sales | 113,781 | 124,127 | 308,350 | 288,613 |
| Gross profit | 86,930 | 114,171 | 234,683 | 251,375 |
| Other costs and expenses: | ||||
| Selling, general and administrative | 251,823 | 313,199 | 642,860 | 1,128,899 |
| Research and development expenses | 1,250 | 22,367 | 46,040 | 76,888 |
| Total operating expenses | 253,073 | 335,566 | 688,900 | 1,205,787 |
| Loss before non-operating income and expense and income taxes | (166,143) | (221,395) | (454,217) | (954,412) |
| Other income and (expense): | ||||
| Other Income | 18 | |||
| Debt discount expense | (64,771) | (84,647) | ||
| Gain/(loss) on derivative | (198,384) | (198,384) | ||
| Interest expense | (15,820) | (8,427) | (39,665) | (35,089) |
| Total Other income (expense) | (278,975) | (8,427) | (322,696) | (35,071) |
| Net Income (Loss) before income taxes | (445,118) | (229,822) | (776,913) | (989,483) |
| Net (Loss) | (445,118) | (229,822) | (776,913) | (989,483) |
| Preferred Stock Dividend | (1,008) | (1,008) | (2,992) | (2,991) |
| Net Income (Loss) attributable to Common Stockholders | $ (446,126) | $ (230,829) | $ (779,905) | $ (992,474) |
| Basic and diluted loss per share | $ (0.01) | $ (0.01) | $ (0.02) | $ (0.03) |
| Weighted average common shares outstanding | 32,271,186 | 31,915,731 | 32,271,186 | 30,690,250 |